What question did this study set out to answer?

This study aims to evaluate the safety and efficacy of Eyevisc™ 2.4% in cataract surgery patients. It seeks to determine the impact on intraocular pressure and visual outcomes.

July 12, 2026Open Access

Safety and Efficacy of Eyevisc™ 2.4% Ophthalmic Viscosurgical Device in Cataract Surgery

SRShreyas RamamurthyACT Foundation DRDandapani RamamurthyACT Foundation BJBhargav JoshiBiotech Park

Key Points

This study aims to evaluate the safety and efficacy of Eyevisc™ 2.4% in cataract surgery patients. It seeks to determine the impact on intraocular pressure and visual outcomes.
Prospective, single-arm, single-center, open-label clinical study
Included 131 patients undergoing cataract surgery
Assessed multiple endpoints including intraocular pressure, endothelial cell density, and visual acuity at various follow-up times (8 hours to 90 days)
No patient experienced an intraocular pressure spike of ≥30 mmHg postoperatively (mean IOP at 90 days was 20.26 ± 1.32 mmHg)
Endothelial cell density was preserved, measuring 2531.28 ± 237.31 cells/mm2 preoperatively and remaining stable at study's end
Visual acuity improved significantly with both uncorrected and corrected distance visual acuity reaching 0.02 ± 0.04 logMAR and 0.00 ± 0.02 logMAR respectively at 90 days (p<0.001)

Abstract

Introduction Hydroxypropyl methylcellulose (HPMC) is a dispersive ophthalmic viscosurgical device (OVD) that provides effective endothelial protection and anterior chamber stability during cataract surgery. However, clinical evidence for individual HPMC formulations remains limited. This study assessed the safety and efficacy of HPMC-based Eyevisc™ 2.4% (Biotech Vision Care Pvt. Ltd., Gujarat, India) in patients undergoing cataract surgery. Methods This was a prospective, single-arm, single-center, open-label clinical study that included patients undergoing cataract surgery, with the primary safety endpoint defined as subjects experiencing at least one postoperative intraocular pressure (IOP) measurement ≥30 mmHg. Other measured factors were endothelial cell density (ECD), visual acuity, corneal thickness, corneal clarity, and intraocular inflammation. Postoperative assessments were conducted at 8 hours (±2 hours), 24 hours (±4 hours), 7 days (±2 days), 30 days (±7 days), and 90 days (±14 days). Results The study included 131 (62 male and 69 female patients) with a mean age of 62 ± 8.16 years. No patient experienced an IOP spike of ≥30 mmHg at any follow-up with a mean of 20.26 ± 1.32 mmHg at 90 days. ECD was 2531.28 ± 237.31 cells/mm2 preoperatively, which remained preserved at the end of the study. Uncorrected and corrected distance visual acuity improved from 0.49 ± 0.27 logMAR and 0.25 ± 0.20 logMAR to 0.02 ± 0.04 logMAR and 0.00 ± 0.02 logMAR, respectively, postoperatively at 90 days (p<0.001, for both). Both corneal clarity and resolution of intraocular inflammation were achieved by 24 hours post-operatively. The surgeon-specific rating was excellent for the "Ease of use" in all cases, and also "Full chamber maintained" was observed in all cases (100%). The study reported no adverse event. Conclusion The study observed no case of the IOP spike, and the ECD was well preserved post-operatively, strongly suggesting the safety and effectiveness of Eyevisc™ 2.4% in patients undergoing cataract surgery.

AIに質問

Bookmark

View Full Paper